Nautilus Biotechnology (NAUT) Investor Summit Virtual Conference summary

Industry context and challenges

• Genomics has advanced significantly, but protein analysis remains a major bottleneck for drug development and precision medicine.

• Current proteomics technologies are inadequate, with poor data quality, lack of reproducibility, and limited coverage of protein forms.

• Most FDA-approved drugs and diagnostics target proteins, yet existing tools fail to provide actionable insights for new therapies.

• Billions are spent annually on research in areas like neurodegeneration, cardiac, and autoimmune diseases, with little breakthrough progress.

• AI's potential in biology is limited by the lack of high-quality, comprehensive proteomics data.

Technology and platform innovation

• Nautilus has developed a disruptive proteomics platform using a novel iterative mapping method, integrating life sciences, engineering, and data science.

• The Voyager instrument, priced around $1 million, enables deep, reproducible protein analysis from various sample types.

• The platform includes proprietary chips, reagents, and advanced software for robust, cloud-based data delivery.

• Consumables are expected to generate significant recurring revenue, with projected pull-through of $500,000 per customer annually.

• Early alpha deployments have generated excitement in the scientific community, with the Buck Institute as a notable early user.

Product roadmap and commercialization

• The tau proteoform assay, targeting Alzheimer's disease, is in early access, with Baylor as the first customer.

• Oncology and Parkinson's disease assays are in development, with the latter supported by a $1.6 million Michael J. Fox Foundation grant.

• Broad scale proteomics application is expected to enter early access in the second half of this year and reach general availability in the first half of next year.

• Initial focus is on academic and nonprofit research, with biopharma engagement expected to grow as applications mature.

• Significant revenue ramp is anticipated once both targeted and broad scale assays are generally available by mid-next year.